Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL JAMES DOWNING

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1639159346
CMS profile
300554
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$626.73

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $626.73 20

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Sage Therapeutics, Inc. $325.00 5
Janssen Pharmaceuticals, Inc $104.32 4
Alkermes, Inc. $75.20 5
ITI, Inc. $39.20 2
AbbVie Inc. $37.62 2
Teva Pharmaceuticals USA, Inc. $26.15 1
Indivior Inc. $19.24 1

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL JAMES DOWNING

NPI 1639159346 · CMS profile ID 300554

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $626.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $32.6111/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102165 CMS
Teva Pharmaceuticals USA, Inc. $26.1511/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056789173 CMS
Alkermes, Inc. $13.9211/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808419 CMS
Indivior Inc. $19.2411/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034223069 CMS
Alkermes, Inc. $15.9609/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808417 CMS
Janssen Pharmaceuticals, Inc $24.9408/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102155 CMS
Alkermes, Inc. $14.7308/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808415 CMS
ITI, Inc. $25.5506/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517805 CMS
Alkermes, Inc. $15.4206/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808413 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017096065 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017097227 CMS
Sage Therapeutics, Inc. $37.5006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017098319 CMS
Sage Therapeutics, Inc. $50.0006/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017102035 CMS
Sage Therapeutics, Inc. $150.0006/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017104067 CMS
Janssen Pharmaceuticals, Inc $24.5105/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102187 CMS
ITI, Inc. $13.6504/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040517795 CMS
AbbVie Inc. $15.4203/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737965 CMS
Alkermes, Inc. $15.1702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022808411 CMS
Janssen Pharmaceuticals, Inc $22.2602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988102175 CMS
AbbVie Inc. $22.2001/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996737959 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $327.48 15
PY2020 $163.49 9
PY2021 $551.28 27
PY2022 $399.89 22
PY2023 $626.73 20
PY2024 $647.99 23
PY2025 $847.36 37

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $914,450.61 88
PY2024 Recipient $2,949.66 2
PY2024 Principal investigator $1,362,460.91 98
PY2023 Recipient $59,611.81 14
PY2023 Principal investigator $997,596.68 181
PY2022 Principal investigator $897,046.39 115
PY2021 Principal investigator $714,455.57 113
PY2020 Principal investigator $1,352,717.69 219
PY2019 Recipient $157,177.13 20
PY2019 Principal investigator $1,373,636.72 268

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,160.25 12/31/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889828395
Principal investigator 1 ABBVIE INC. $154.50 12/31/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. No dispute reported 06/30/2026 965540001
Principal investigator 1 ABBVIE INC. $231.75 12/31/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 965540325
Principal investigator 1 Sage Therapeutics, Inc. $19,542.51 12/14/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905461039
Principal investigator 1 ABBVIE INC. $1,000.00 12/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889824929
Principal investigator 1 ABBVIE INC. $21,618.00 12/07/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889823387
Principal investigator 1 ABBVIE INC. $3,004.00 12/07/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889823589
Principal investigator 1 ABBVIE INC. $3,600.00 12/01/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889822359
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $130.00 11/30/2022 Non-covered Recipient Entity
Future Search Trials Dallas Clinic
PoCC study in patients with PTSD No dispute reported 06/30/2026 946866727
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,156.50 11/17/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 4 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens No dispute reported 06/30/2026 933402409
Principal investigator 1 Sage Therapeutics, Inc. $3,056.04 11/16/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905460601
Principal investigator 1 Sage Therapeutics, Inc. $7,201.35 11/09/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905460427
Principal investigator 1 ABBVIE INC. $26,445.50 11/08/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889818649
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,587.49 11/03/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933402131
Principal investigator 1 Sage Therapeutics, Inc. $132,090.66 11/02/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905460009
Principal investigator 1 Sage Therapeutics, Inc. $659.88 10/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905459717
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,700.00 10/20/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933401539
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,000.00 10/20/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 4 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens No dispute reported 06/30/2026 933401627
Principal investigator 1 Sage Therapeutics, Inc. $2,999.88 10/19/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905459519
Principal investigator 1 Sage Therapeutics, Inc. $7,167.42 10/12/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905459121
Principal investigator 1 Sage Therapeutics, Inc. $2,114.19 10/12/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905459127
Principal investigator 1 ABBVIE INC. $34,112.50 10/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889814105
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,250.00 10/06/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 4 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens No dispute reported 06/30/2026 933401253
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,243.37 09/29/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952929235
Principal investigator 1 Sage Therapeutics, Inc. $7,423.65 09/22/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905458745
Principal investigator 1 Eisai Inc. $2,570.00 09/16/2022 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926003565
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,295.04 09/15/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933400245
Principal investigator 1 ABBVIE INC. $29,304.50 09/08/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889809163
Principal investigator 1 Sage Therapeutics, Inc. $10,348.65 09/08/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905458405
Principal investigator 1 ABBVIE INC. $2,000.00 09/06/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889808303
Principal investigator 1 ABBVIE INC. $440.00 09/06/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889808305
Principal investigator 1 Sage Therapeutics, Inc. $5,035.68 08/24/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905458105
Principal investigator 1 Sage Therapeutics, Inc. $5,564.52 08/17/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905457925
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,818.40 08/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933397081
Principal investigator 1 Sage Therapeutics, Inc. $8,026.20 08/10/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905457697
Principal investigator 1 ABBVIE INC. $8,107.00 08/04/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889803451
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,959.33 08/01/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952928463
Principal investigator 1 Sage Therapeutics, Inc. $4,471.74 07/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905457331
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,144.37 07/21/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933394191
Principal investigator 1 Sage Therapeutics, Inc. $10,931.31 07/20/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905456957
Principal investigator 1 ABBVIE INC. $1,000.00 07/18/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. No dispute reported 06/30/2026 889801373
Principal investigator 1 Sage Therapeutics, Inc. $16,394.04 07/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905456643
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,081.20 07/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933392853
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,702.50 07/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933392865
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $300.00 07/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933392873
Principal investigator 1 ABBVIE INC. $9,751.50 07/01/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889797801
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $17,888.68 06/23/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933391241
Principal investigator 1 Purdue Pharma L.P. $3,828.15 06/22/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 949672635
Principal investigator 1 Sage Therapeutics, Inc. $4,784.13 06/22/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905456009
Principal investigator 1 ABBVIE INC. $11,830.50 06/21/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889796523
Principal investigator 1 Sage Therapeutics, Inc. $8,413.47 06/15/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905455757
Principal investigator 1 Sage Therapeutics, Inc. $7,679.88 06/08/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905455573
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,700.00 06/02/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933389117
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,002.55 05/31/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952928215
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,323.70 05/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388517
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,682.00 05/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388539
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $54,788.00 05/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 933761337
Principal investigator 1 Sage Therapeutics, Inc. $3,073.85 05/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905455289
Principal investigator 1 Purdue Pharma L.P. $552.90 05/25/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 949672633
Principal investigator 1 Sage Therapeutics, Inc. $12,213.63 05/25/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905455235
Principal investigator 1 Sage Therapeutics, Inc. $3,251.43 05/18/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454975
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $600.00 05/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933387274
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,250.00 05/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933387281
Principal investigator 1 Sage Therapeutics, Inc. $7,557.03 05/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454631
Principal investigator 1 Sage Therapeutics, Inc. $5,750.00 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454201
Principal investigator 1 Sage Therapeutics, Inc. $2,000.00 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454207
Principal investigator 1 Sage Therapeutics, Inc. $620.00 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454213
Principal investigator 1 Sage Therapeutics, Inc. $2,950.00 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454219
Principal investigator 1 Sage Therapeutics, Inc. $5,232.50 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454225
Principal investigator 1 Sage Therapeutics, Inc. $9,272.20 05/05/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454231
Principal investigator 1 ABBVIE INC. $3,629.00 05/04/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants No dispute reported 06/30/2026 889789487
Principal investigator 1 ABBVIE INC. $8,500.00 05/04/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889789489
Principal investigator 1 Sage Therapeutics, Inc. $4,027.14 05/04/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905454149
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,700.00 04/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933385741
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,500.00 04/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933385747
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,700.00 04/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age No dispute reported 06/30/2026 933386285
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $7,296.09 04/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933386292
Principal investigator 1 Sage Therapeutics, Inc. $7,036.38 04/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905453819
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,750.00 04/21/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933384859
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $515.00 04/21/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933384865
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $825.00 04/21/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933384873
Principal investigator 1 Sage Therapeutics, Inc. $2,834.91 04/20/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905453433
Principal investigator 1 Sage Therapeutics, Inc. $2,969.46 04/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905453193
Principal investigator 1 Purdue Pharma L.P. $948.00 04/11/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 949672631
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $9,214.05 04/07/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933383879
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,750.00 04/07/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933383887
Principal investigator 1 Sage Therapeutics, Inc. $5,335.20 03/30/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905452943
Principal investigator 1 Supernus Pharmaceuticals, Inc. $441.51 03/25/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952927693
Principal investigator 1 Sage Therapeutics, Inc. $2,178.54 03/23/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905452451
Principal investigator 1 Allergan, Inc. $2,125.00 03/18/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 864375175
Principal investigator 1 Eisai Inc. $1,500.00 03/18/2022 Non-covered Recipient Entity
FUTURE SEARCH TRIALS OF NEUROLOGY
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 926003563
Principal investigator 1 Purdue Pharma L.P. $500.00 03/18/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States No dispute reported 06/30/2026 949672637
Principal investigator 1 Allergan, Inc. $90.00 03/16/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 864375119
Principal investigator 1 Sage Therapeutics, Inc. $26,743.86 03/16/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905451871
Principal investigator 1 Allergan, Inc. $11,076.80 03/08/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864374121
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,959.33 03/02/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952927235
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $12,639.47 02/24/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380789
Principal investigator 1 Allergan, Inc. $4,427.95 02/17/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864370633
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,624.75 02/10/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933379633
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,500.00 02/10/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933379639
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,700.00 02/03/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age No dispute reported 06/30/2026 933379137
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $989.90 01/28/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378277
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,000.00 01/28/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378441
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,510.00 01/28/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378449
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $5,936.27 01/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF NEUROLOGY LP
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933377953
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,122.08 01/27/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SPN-812 IN ADULTS WITH ATTENTION- DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 952926839
Principal investigator 1 Sage Therapeutics, Inc. $65,507.13 01/26/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJECTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905450395
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,500.00 01/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376933
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,140.00 01/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376941
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,025.00 01/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376949
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $250.00 01/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376957
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $75.00 01/13/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933376965
Principal investigator 1 Allergan, Inc. $47,027.85 01/12/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE TREATMENT OF MIGRAINE WHEN ADMINSTERED DURING THE PREMONITORY PHASE No dispute reported 06/30/2026 864367023
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,638.00 01/10/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS
A randomized double-blind placebo-controlled trial of adjunctive Troriluzole in Obsessive Compulsive Disorder No dispute reported 06/30/2026 933376815
Principal investigator 1 Sage Therapeutics, Inc. $6,147.70 01/06/2022 Non-covered Recipient Entity
FUTURESEARCH TRIALS OF DALLAS LP
A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 905450085